Physician profile
Betty L Herrington
NPI 1437363967
$22,913.20
in general payments reported to CMS, 2019-2025
26 companies · $16K in 2025
The $16K reported for 2025 was more than what 89% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $114 · 2021: $31.72 · 2022: $19.87 · 2023: $73.93 · 2024: $6,756 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $3,231 · Consulting Fee: $1,875 · Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,470.00 |
| Travel and Lodging | $3,231.41 |
| Consulting Fee | $1,875.00 |
| Food and Beverage | $934.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Day One Biopharmaceuticals | $21,966.29 | 2024-2025 | Ojemda |
| Csl Behring | $90.54 | 2019-2024 | Idelvion, Hemgenix |
| Novo Nordisk INC | $79.87 | 2019-2025 | Alhemo, Esperoct |
| Merck Sharp & Dohme LLC | $78.47 | 2019-2025 | Prevymis |
| Servier Pharmaceuticals LLC | $72.61 | 2019-2020 | |
| Springworks Therapeutics, INC. | $67.83 | 2024-2025 | Gomekli, Ogsiveo |
| Novartis Pharmaceuticals Corporation | $66.20 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $61.07 | 2023-2024 | Koselugo |
| Pfizer INC. | $56.30 | 2025 | |
| Jazz Pharmaceuticals INC. | $54.93 | 2019-2024 | |
| Amgen INC. | $46.86 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $35.37 | 2024 | Clonoseq |
| Global Blood Therapeutics, INC. | $30.65 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.70 | 2020 | |
| Teleflex LLC | $25.75 | 2025 | Arrow |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rare Disease Therapeutics, INC. | $24.28 | 2025 | Xromi |
| Mesoblast, INC. | $23.30 | 2025 | Ryoncil |
| Celgene Corporation | $21.39 | 2025 | Breyanzi |
| Sanofi-Aventis U.S. LLC | $18.94 | 2019 | |
| Emmaus Medical, INC. | $16.91 | 2019 | |
| Adma Biomanufacturing LLC | $16.70 | 2020 | |
| Grifols USA, LLC | $15.38 | 2019 | |
| Sobi, INC | $14.86 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Herrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.